Skip to main content
BIOVIE INC. logo

BIOVIE INC. — Investor Relations & Filings

Ticker · BIVI ISIN · US09074F4054 US Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2019-04-27 Proxy Solicitation & In…
Country US United States of America
Listing US BIVI

About BIOVIE INC.

https://www.bioviepharma.com/

BioVie Inc. is a clinical-stage biopharmaceutical company that develops drug therapies for chronic debilitating conditions. The company's pipeline focuses on neurological and neurodegenerative disorders as well as advanced liver disease. Its lead drug candidate, bezisterim, is being studied for Alzheimer's disease based on the hypothesis that modulating inflammation and enhancing insulin sensitivity in the brain can improve cognitive function and provide neuroprotection. Other areas of focus include Parkinson's disease, ascites (a common complication of advanced liver cirrhosis), and Long COVID. The company also conducts research into epigenetic mechanisms, such as DNA methylation, to understand gene expression regulation.

Recent filings

Filing Released Lang Actions
PRE 14C
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14C Information Statement pursuant to Section 14(c) of the Securities Exchange Act of 1934. It details corporate actions including a reverse stock split and adoption of an equity incentive plan. It explicitly states it is an Information Statement and not a proxy solicitation, and it provides detailed information about the corporate actions to be taken. This type of filing is used to inform shareholders of corporate actions without requesting a vote or proxy. The document is not a financial report, earnings release, or management discussion, nor is it a proxy solicitation or voting results announcement. It fits the category of Proxy Solicitation & Information Statement (PSI) as it provides information to shareholders to inform them about corporate actions and related matters, even though no vote is requested. The length and detail confirm it is the statement itself, not just an announcement of a report. Therefore, the correct classification is PSI with high confidence.
2019-04-27 English
Regulatory Filings 2019
Regulatory Filings
2019-04-24 English
POS AM NO.1
Transaction in Own Shares Classification · 95% confidence The document is titled 'POST EFFECTIVE AMENDMENT NO. 1 To FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933' and is filed with the SEC. It discusses the deregistration of securities and the termination of a common stock purchase agreement. The content is focused on amendments to a registration statement related to securities offerings, not on financial results, management changes, or other report types. The document is about a post-effective amendment to a registration statement, which is a regulatory filing related to capital markets and securities registration. It is not a financial report, earnings release, or management discussion. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS), as it relates to the deregistration and termination of securities offerings and the removal of unsold securities from registration under the Form S-1.
2019-04-18 English
PRIMARY DOCUMENT
Director's Dealing
2019-03-20 English
PRIMARY DOCUMENT
Director's Dealing
2019-03-14 English
PRIMARY DOCUMENT
Director's Dealing
2019-03-13 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.